ELEVATING EXPECTATIONS IN PET CARE PetMedix is delivering the next generation of proven monoclonal antibody technology to provide unprecedented therapeutic options for pets. Read More OUR STORY PetMedix leverages an experienced scientific team and decades of human clinical research to develop fully species-specific, naturally generated therapeutic antibodies for pets. Here are some key moments in … Home Read More »
Investors 1
| Date | Name | Website |
| 18.05.2023 | Cambridge ... | cic.vc |
Mentions in press and media 5
| Date | Title | Description | Source |
| 27.10.2023 | Parkwalk – Acquisition of PetMedix | Parkwalk are delighted to announce the acquisition of our portfolio company PetMedix, generating a p... | parkwalkad... |
| 01.03.2023 | Parkwalk – Meet the Portfolio series | As part of our annual Portfolio Showcase in 2022, we had the opportunity to sit down with some of ou... | parkwalkad... |
| 18.01.2023 | Pettech in Europe is pawsitively booming with investors lini... | Over the last few years, one trend in tech investment shows no sign of abating – pettech. Early-stag... | tech.eu/20... |
| 07.01.2022 | PetMedix enters into antibody discovery collaboration with Z... | PetMedix enters into antibody discovery collaboration with Zoetis 07-01-2022 PetMedix™ is pleased ... | cambridgen... |
| 07.01.2022 | PetMedix enters into antibody discovery collaboration with Z... | PetMedix enters into antibody discovery collaboration with Zoetis PetMedix™ is pleased to announce ... | cic.vc/new... |